Source: Annual Congress 2003 - Pulmonary circulation
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Wahn, H. Kaufmann, F. Finter, G. Ertl, M. Schmidt (Wurzburg, Germany). Pulmonary artery pressure (PAP) reduction by systemic and inhaled nitroglycerin (NTG) in an isolated rabbit lung model of pulmonary hypertension (PH). Eur Respir J 2003; 22: Suppl. 45, 1766

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary artery pressure (PAP) is reduced by inhaled sodium nitroprusside (SNP) in an isolated lung model of pulmonary hypertension: comparison with systemic application Source: Eur Respir J 2002; 20: Suppl. 38, 4s Year: 2002 Pulmonary artery pressure (PAP) reduction by systemic and inhaled S-nitroso-N-acetyl-penicillamine (SNAP) in an isolated rabbit lung model of acute lung injury Source: Eur Respir J 2002; 20: Suppl. 38, 37s Year: 2002 Epoprostenol (EPT) for acute reactivity testing (AVT) in pulmonary artery hypertension (PAH) Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004 Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Comparison of subcutaneous (sc) treprostinil use for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in 2 Belgian centers Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010 The right ventricle (RV) in systemic sclerosis-associated pulmonary arterial hypertension (SSCPH) vs idiopathic pulmonary arterial hypertension (IPH): higher inflammatory status, no increase in interstitial fibrosis Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Is there a fixed relationship between the mean and systolic pulmonary artery pressures in idiopathic pulmonary arterial hypertension (IPAH) and proximal chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2009 - Pulmonary embolism Year: 2009 Acute exacerbation of idiopathic pulmonary fibrosis is associated to increase of pulmonary artery systolic pressure (PAPs) Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Effects of amlodipine on pulmonary haemodynamics in pulmonary hypertension (PH) secondary to chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 27s Year: 2002 Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Pulmonary hypertension (PH) and features of pulmonary circulation in patient with lung sarcoidosis (LS) Source: Eur Respir J 2006; 28: Suppl. 50, 354s Year: 2006 Patterns of mean pulmonary artery pressure (mPAP)-flow relation changes following chronic therapy in idiopathic pulmonary arterial hypertension (IPAH) Source: Eur Respir J 2006; 28: Suppl. 50, 427s Year: 2006 Mean pulmonary artery pressure-heart rate (mPAP-HR) relationship during submaximal supine exercise in idiopathic pulmonary arterial hypertension (iPAH) Source: Annual Congress 2005 - Exercise in pulmonary hypertension Year: 2005 VENTASWITCH study: Switching from Ventavis (iloprost) V10 to V20 improves inhalation behaviour in patients with pulmonary arterial hypertension (PAH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 6MWD in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 464s Year: 2003 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1 Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Sitaxsentan improves 6MW and hemodynamics in patients with pulmonary arterial hypertension (PAH) related to connective tissue disease (CTD) Source: Eur Respir J 2005; 26: Suppl. 49, 564s Year: 2005 Safety and tolerability of rapid dose-titration of subcutaneous (SC) treprostinil in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015